POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer; and PNT-2004, a fibroblast activation protein-a targeted radioligand to treat solid tumors. POINT Biopharma Global Inc. is based in Indianapolis, Indiana.
IPO Year: 2020
Exchange: NASDAQ
Website: pointbiopharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/20/2023 | $12.00 → $14.00 | Buy | Jefferies |
| 12/14/2022 | $10.00 | Outperform | Raymond James |
| 11/30/2022 | $14.00 | Outperform | SVB Leerink |
| 10/11/2022 | $20.00 | Outperform | Oppenheimer |
| 9/16/2022 | $22.00 | Buy | Truist |
| 9/14/2022 | $20.00 | Buy | Berenberg |
| 8/16/2022 | $20.00 | Buy | Guggenheim |
| 7/6/2022 | Outperform | William Blair | |
| 5/26/2022 | $7.00 → $20.00 | Hold → Buy | Jefferies |
| 12/17/2021 | $65.00 | Underperform | Mizuho |
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ:PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly. "We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we
15-12G - POINT Biopharma Global Inc. (0001811764) (Filer)
EFFECT - POINT Biopharma Global Inc. (0001811764) (Filer)
EFFECT - POINT Biopharma Global Inc. (0001811764) (Filer)
POS AM - POINT Biopharma Global Inc. (0001811764) (Filer)
POS AM - POINT Biopharma Global Inc. (0001811764) (Filer)
S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)
S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)
S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)
25-NSE - POINT Biopharma Global Inc. (0001811764) (Subject)
8-K - POINT Biopharma Global Inc. (0001811764) (Filer)
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, c
INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and Athebio AG ("Athebio"), an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), today announced a collaboration and license agreement to develop and commercialize DARPin-targeted radioligands ("Radio-DARPins"). DARPins are an attractive ligand class for cell-surface targets that could enable access to cell "surfaceome" targets beyond catalytic and ligand binding sites typically ac
INDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the filling of its vacant board seat with the appointment of Bridget Martell, M.A., M.D. to its Board of Directors. "On behalf of POINT and the Board of Directors, I am pleased to welcome Dr. Martell, an experienced biotech board executive who brings extensive drug development, operational, and commercial expertise in both oncology and precision medicine," said Allan Silber, Executive Chairman of POINT Biopharma. "Her experience and perspectives will b
Mr. Horvath will lead the commercialization of POINT's pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer Radioligand Therapy Franchise at Advanced Accelerator Applications (a Novartis Company) INDIANAPOLIS, June 21, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the appointment of Chris Horvath, as Executive Vice President, Commercial. Mr. Horvath brings almost twenty years of experience in the pharmaceutical industry, having led or wo
INDIANAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the appointment of Matthew Vincent, Ph.D., J.D., as Senior Vice President, Business Development. Dr. Vincent brings more than 25 years of pharma business development experience through a variety of partnering, licensing, and M&A transactions and will lead licensing activities for POINT, with a focus on expansion into the Asian markets and strategic partnerships to fully realize the potential of POINT's pan-cancer targeting technologies. Dr. Vincent's d
Jefferies resumed coverage of POINT Biopharma with a rating of Buy and set a new price target of $14.00 from $12.00 previously
Raymond James initiated coverage of POINT Biopharma with a rating of Outperform and set a new price target of $10.00
SVB Leerink initiated coverage of POINT Biopharma with a rating of Outperform and set a new price target of $14.00
Oppenheimer initiated coverage of POINT Biopharma with a rating of Outperform and set a new price target of $20.00
Truist initiated coverage of POINT Biopharma with a rating of Buy and set a new price target of $22.00
Berenberg initiated coverage of POINT Biopharma with a rating of Buy and set a new price target of $20.00
Guggenheim initiated coverage of POINT Biopharma with a rating of Buy and set a new price target of $20.00
William Blair initiated coverage of POINT Biopharma with a rating of Outperform
Jefferies upgraded POINT Biopharma from Hold to Buy and set a new price target of $20.00 from $7.00 previously
Mizuho initiated coverage of POINT Biopharma Global with a rating of Underperform and set a new price target of $65.00
SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)
SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)
SC 13D - POINT Biopharma Global Inc. (0001811764) (Subject)
SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)
SC 13G/A - POINT Biopharma Global Inc. (0001811764) (Subject)
SC 13G - POINT Biopharma Global Inc. (0001811764) (Subject)
SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)
SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)
SC 13G - POINT Biopharma Global Inc. (0001811764) (Subject)
SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ:PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly. "We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, c
Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- December 18, 2023 – Lantheus Holdings, Inc. (Lantheus) (NASDAQ:LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ:PNT) today announced statistically significant topline results from the pivotal Phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (AR
INDIANAPOLIS, Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ:PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern time, on Dec. 15, 2023, has been extended until 5:00 p.m., Eastern time, on Dec. 22, 2023, unless the tender offer is further extended or earlier terminated, in order for the parties to satisfy the minimum tender condition. All regulatory app
INDIANAPOLIS, Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ:PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern time, on Dec. 1, 2023, has been extended until 5:00 p.m., Eastern time, on Dec. 15, 2023, unless the tender offer is further extended or earlier terminated, in order for the parties to satisfy the minimum tender condition. All regulatory appro
INDIANAPOLIS, Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ:PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern time, on Nov. 16, 2023, has been extended until 5:00 p.m., Eastern time, on Dec. 1, 2023, unless the tender offer is further extended or earlier terminated, in order for the parties to satisfy the minimum tender condition. All regulatory appr
INDIANAPOLIS, Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ:PNT) radioactive materials license (the "NRC Consent"), which will occur following the completion of Lilly's previously announced tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. Obtaining the NRC Consent is the last regulatory approval necessary for the consummation of the transaction. The t
INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. "The founding mission of our company is to accelerate the discovery, development and global access to radiopharmaceuticals," said Joe McCann, Ph.D., CEO of POINT Biopharma. "I view Lilly's agreement to acquire POINT as validation of the uniqueness of our team, infrastructure and pipeline. Together, we can become a global radiopharmaceutical leader, executi
INDIANAPOLIS, Oct. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and POINT Biopharma Global, Inc. (NASDAQ:PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. Radioligand therapy can enable the precise targeting of cancer by linking a radioisotope to a targeting molecule that delivers radiation directly to cancer cells, enabling significant anti-tumor efficacy while limiting the impact to healthy tissue. POINT's lead programs are in late-phase development. PNT20021 is a prostate-specific membrane antigen (PSMA) targete